EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Use of Nonhuman Primate Models for Advancing HIV PrEP

Elena Bekerman, Christian Callebaut

Viruses · 30.08.2025 · 17 (9) · 1192

DOI: 10.3390/v17091192 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 30.08.2025. Verfasst von Elena Bekerman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences Inc., Foster City, CA 94404, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Disease Models, Animal, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global fight against HIV/AIDS has been significantly bolstered by the development and implementation of pre-exposure prophylaxis (PrEP), yet innovation in PrEP interventions, improved adherence and greater access are still needed to maximize its benefit. Nonhuman primate (NHP) infection with simian immunodeficiency virus (SIV) has served as an instrumental animal model in advancing HIV PrEP research. This review comprehensively examines the utility of NHP models in evaluating the efficacy, pharmacokinetics, and safety of diverse PrEP strategies, including oral, injectable, implantable, and topical formulations. It discusses the development of diverse challenge models that simulate human transmission routes and the advantages of NHPs in enabling controlled and mechanistically informative studies. It also highlights the successful translation of pivotal NHP studies evaluating tenofovir-based regimens as well the long-acting agents, cabotegravir and lenacapavir, into the clinical settings, emphasizing the consistently high predictive power of the NHP models for the HIV PrEP clinical efficacy. Finally, it underscores the importance of species-specific pharmacologic considerations and the value of NHP data in informing clinical trial design. As the global community strives to end the HIV epidemic as a public health threat in the absence of an efficacious prophylactic vaccine, NHP models make a critical contribution in the development of next-generation HIV prevention tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisHIV InfectionsDisease Models, AnimalAnti-HIV AgentsAnimalsHumansSimian Immunodeficiency VirusPrimatesSimian Acquired Immunodeficiency SyndromeTenofovir

Stichwörter der Autor:innen

HIVPrEPSIVnonhuman primate modelsprevention

Substanzen

Anti-HIV AgentsTenofovir

Autor:innen und Institutionen

  • Gilead Sciences Inc., Foster City, CA 94404, USA.

Förderung

  • Gilead Sciences, Inc.

Zitieren

APA

Bekerman, E., & Callebaut, C. (2025). The Use of Nonhuman Primate Models for Advancing HIV PrEP. Viruses, 17(9), 1192. https://doi.org/10.3390/v17091192

Vancouver

Bekerman E, Callebaut C. The Use of Nonhuman Primate Models for Advancing HIV PrEP. Viruses. 2025;17(9):1192. doi:10.3390/v17091192

BibTeX
@article{Bekerman2025,
  author = {Bekerman, Elena and Callebaut, Christian},
  title = {The Use of Nonhuman Primate Models for Advancing HIV PrEP},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1192},
  doi = {10.3390/v17091192}
}
Kostenlos starten →